

Technology Development Group

Request Information

Catalytic MicroRNA Antagonists

Tech ID: 29809 / UC Case 2016-592-0

SUMMARY

UCLA researchers in the Department of Biological Chemistry have developed a novel approach for miRNA inhibition.

BACKGROUND

Micro RNA (miRNA) are short, 22 nucleotide RNA sequences. They play a critical role in post-transcription gene regulation and their misregulation is associated with different diseases such as cancer, autoimmunity, and metabolic diseases. Therapeutic strategies that require elimination of the miRNA use complementary RNA sequences that bind the target miRNA and inhibit its normal function. However, this approach is highly inefficient, as it needs stoichiometric amounts of the antagonist.

INNOVATION

UCLA researchers have designed novel miRNA antagonists. Their approach uses modified antagonists with increased activity and results in clearance of the target miRNA. These antagonists are powerful tools for therapeutic purposes and as research tools to characterize miRNAs with unknown functions.

APPLICATIONS

- ▶ Inhibition of target miRNA for therapeutic purposes in cancer, autoimmune and other diseases
- Research tool for knockout studies

ADVANTAGES

- ▶ Higher efficiency than current antagonists
- Simple and easy to use

STATE OF DEVELOPMENT

Currently being tested.

Available Technologies

Contact Our Team

Permalink

CONTACT

UCLA Technology Development Group ncd@tdg.ucla.edu tel: 310.794.0558.



INVENTORS

Guo, Feng

OTHER INFORMATION

KEYWORDS microRNA, antagonist, cancer, miRNA

knock down, miRNA inhibition

CATEGORIZED AS

Medical

- Therapeutics
- Research Tools
 - Nucleic Acids/DNA/RNA

RELATED CASES

2016-592-0

Gateway to Innovation, Research and Entrepreneurship

UCLA Technology Development Group

10889 Wilshire Blvd., Suite 920,Los Angeles,CA 90095 https://tdg.ucla.edu Tel: 310.794.0558 | Fax: 310.794.0638 | ncd@tdg.ucla.edu © 2018, The Regents of the University of California Terms of use Privacy Notice

